Cargando…
Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823876/ https://www.ncbi.nlm.nih.gov/pubmed/33401634 http://dx.doi.org/10.3390/antibiotics10010040 |
_version_ | 1783639940823777280 |
---|---|
author | Gur, David Chitlaru, Theodor Mamroud, Emanuelle Zauberman, Ayelet |
author_facet | Gur, David Chitlaru, Theodor Mamroud, Emanuelle Zauberman, Ayelet |
author_sort | Gur, David |
collection | PubMed |
description | Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is delayed for longer than 24 h after symptom onset. To overcome the emergence of antibiotic resistant strains, we attempted a systematic screening of Food and Drug Administration (FDA)-approved drugs to identify alternative compounds which may possess antibacterial activity against Y. pestis. Here, we describe a drug-repurposing approach, which led to the identification of two antibiotic-like activities of the anticancer drugs bleomycin sulfate and streptozocin that have the potential for designing novel antiplague therapy approaches. The inhibitory characteristics of these two drugs were further addressed as well as their efficiency in affecting the growth of Y. pestis strains resistant to doxycycline and ciprofloxacin, antibiotics recommended for plague treatment. |
format | Online Article Text |
id | pubmed-7823876 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78238762021-01-24 Screening of an FDA-Approved Library for Novel Drugs against Y. pestis Gur, David Chitlaru, Theodor Mamroud, Emanuelle Zauberman, Ayelet Antibiotics (Basel) Article Yersinia pestis is a Gram-negative pathogen that causes plague, a devastating disease that kills millions worldwide. Although plague is efficiently treatable by recommended antibiotics, the time of antibiotic therapy initiation is critical, as high mortality rates have been observed if treatment is delayed for longer than 24 h after symptom onset. To overcome the emergence of antibiotic resistant strains, we attempted a systematic screening of Food and Drug Administration (FDA)-approved drugs to identify alternative compounds which may possess antibacterial activity against Y. pestis. Here, we describe a drug-repurposing approach, which led to the identification of two antibiotic-like activities of the anticancer drugs bleomycin sulfate and streptozocin that have the potential for designing novel antiplague therapy approaches. The inhibitory characteristics of these two drugs were further addressed as well as their efficiency in affecting the growth of Y. pestis strains resistant to doxycycline and ciprofloxacin, antibiotics recommended for plague treatment. MDPI 2021-01-03 /pmc/articles/PMC7823876/ /pubmed/33401634 http://dx.doi.org/10.3390/antibiotics10010040 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gur, David Chitlaru, Theodor Mamroud, Emanuelle Zauberman, Ayelet Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title | Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title_full | Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title_fullStr | Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title_full_unstemmed | Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title_short | Screening of an FDA-Approved Library for Novel Drugs against Y. pestis |
title_sort | screening of an fda-approved library for novel drugs against y. pestis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823876/ https://www.ncbi.nlm.nih.gov/pubmed/33401634 http://dx.doi.org/10.3390/antibiotics10010040 |
work_keys_str_mv | AT gurdavid screeningofanfdaapprovedlibraryfornoveldrugsagainstypestis AT chitlarutheodor screeningofanfdaapprovedlibraryfornoveldrugsagainstypestis AT mamroudemanuelle screeningofanfdaapprovedlibraryfornoveldrugsagainstypestis AT zaubermanayelet screeningofanfdaapprovedlibraryfornoveldrugsagainstypestis |